Hot Movers: Molycorp Inc (NYSE:MCP), DryShips Inc. (NASDAQ:DRYS), Dendreon Corporation (NASDAQ:DNDN)

Lakeway, NY -- (SBWIRE) -- 02/25/2013 -- ThePennyStockProfiler.com, an investment community with a special focus on updating investors with recent news on the U.S. stock market, issues news alert on the following stocks:-

Molycorp Inc (NYSE:MCP) shares jumped 0.15% and closed at $6.63 in the last trading session. The company, on Jan. 25, announced the pricing of its previously announced public offering of 37,500,000 shares of its common stock (the "Common Stock") (or up to an aggregate of 43,125,000 shares of Common Stock if the underwriters of such offering exercise their option to purchase additional shares of Common Stock in full) at a price per share of $6.00 (the "Primary Shares Offering") and $150 million aggregate principal amount (or up to an aggregate of $172.5 million aggregate principal amount if the underwriters of such offering exercise their over-allotment option in full) of its 5.50% Convertible Senior Notes due 2018 (the "Notes") (the "Notes Offering") in separate registered public offerings.

Is MCP a Strong Buy After The Recent Gain? Let’s Find out Here

DryShips Inc. (NASDAQ:DRYS) shares declined 2.96% to $1.97. The company, on Feb. 12, announced the upsizing of the previously announced public offering of common shares of Ocean Rig that it owns to 7,500,000 common shares and that the offering has priced with gross proceeds of approximately $126.4 million.

Following the completion of the offering, DryShips is expected to own approximately 59.4% of Ocean Rig's outstanding shares. The offering is expected to close on February 14, 2013. Deutsche Bank Securities and Credit Suisse are acting as joint book-running managers for the offering.

Is DRYS a Strong Buying Opportunity After The Recent Slump? Find out Here

Dendreon Corporation (NASDAQ:DNDN) shares fell 1.56% and closed at $5.67. The company, on Feb. 13, announced that results from several ongoing or completed studies investigating the utility of PROVENGE (sipuleucel-T) in the treatment of advanced prostate cancer, including studies that may lead to new treatment approaches, as well as the investigational immunotherapy DN24-02 in patients with surgically-resected urothelial cancer, will be presented at the 2013 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium in Orlando, Florida, from February 14-16, 2013.

Should Investors Consider DNDN After The Recent price Action? Get Free Trend Analysis Here

About ThePennyStockProfiler.com
ThePennyStockProfiler.com is engaged in providing the most up to date and useful information on Microcap Stocks poised to breakout. ThePennyStockProfiler.com also provides investors with trend analysis, detailed company profiles, and most importantly a much needed "informational edge" which can be used as a tool for making investment decisions. To Receive Instant updates in the inbox, readers are advised to sign up for free at http://www.ThePennyStockProfiler.com

Disclaimer
The assembled information disseminated by ThePennyStockProfiler.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. ThePennyStockProfiler.com does expect that investors will buy and sell securities based on information assembled and presented in phd-trading.com. PLEASE always do your own due diligence, and consult your financial advisor.